Search Results - "BOTTA‐FRIDLUND, D."

Safety of sofosbuvir‐based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study by Anty, R., Favre, G., Coilly, A., Rossignol, E., Houssel‐Debry, P., Duvoux, C., De Ledinghen, V., Di Martino, V., Leroy, V., Radenne, S., Kamar, N., Canva, V., D'Alteroche, L., Durand, F., Dumortier, J., Lebray, P., Besch, C., Tran, A., Canivet, C. M., Botta‐Fridlund, D., Montialoux, H., Moreno, C., Conti, F., Silvain, C., Perré, P., Habersetzer, F., Abergel, A., Debette‐Gratien, M., Dharancy, S., Esnault, V. L. M., Fougerou‐Leurent, C., Cagnot, C., Diallo, A., Veislinger, A., Danjou, H., Samuel, D., Pageaux, G.‐P., Duclos‐Vallée, J.‐C.

“…Summary Background In liver transplant recipients with hepatitis C virus recurrence, there is concern about renal safety of sofosbuvir‐based regimens. Changes…”
Get full text

Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies by Bourliere, M., Penaranda, G., Renou, C., Botta-Fridlund, D., Tran, A., Portal, I., Lecomte, L., Castellani, P., Rosenthal-Allieri, M. A., Gerolami, R., Ouzan, D., Deydier, R., Degott, C., Halfon, P.

“…Noninvasive indexes have been developed to predict fibrosis staging. The aim of this study was to assess the diagnostic accuracy of these indexes in comparison…”
Get full text

Optimized stepwise combination algorithms of non‐invasive liver fibrosis scores including Hepascore in hepatitis C virus patients by BOURLIERE, M., PENARANDA, G., OUZAN, D., RENOU, C., BOTTA‐FRIDLUND, D., TRAN, A., ROSENTHAL, E., WARTELLE‐BLADOU, C., DELASALLE, P., OULES, V., PORTAL, I., CASTELLANI, P., LECOMTE, L., ROSENTHAL‐ALLIERI, M. A., HALFON, P.

“…Summary Background  Non‐invasive liver fibrosis scores such as Hepascore (HS) have been proposed as an alternative to liver biopsy in hepatitis C virus…”
Get full text

47 EFFICACY AND SAFETY OF PROTEASE INHIBITORS FOR SEVERE HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A FIRST MULTICENTRIC EXPERIENCE by Coilly, A, Roche, B, Botta-Fridlund, D, Leroy, V, Pageaux, P.G, Si-Ahmed, S.N, Antonini, T.M, Samuel, D, Duclos-Vallee, J.-C

Get full text

Detection of rare hepatitis C viruses of subtype 4r in Southeastern France by Dubourg, L., Gerolami, R., Borentain, P., Tamalet, C., Mokhtari, S., Botta-Fridlund, D., Aherfi, S., Colson, P.

Get full text

The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt (TIPS) placement by Borentain, P, Soussan, J, Resseguier, N, Botta-Fridlund, D, Dufour, J.-C, Gérolami, R, Vidal, V

“…Abstract Purpose The goal of this study was to identify clinical and imaging variables that are associated with an unfavorable outcome during the 30 days…”
Get full text

Sofosbuvir-Based-Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation : Results from the ANRS CO23 Cupilt Study by Dharancy, S, Coilly, A, Fougerou-Leurent, C, Duvoux, C, Kamar, N, Leroy, V, Tran, A, Houssel-Debry, P, Canva, V, Moreno, C, Conti, F, Dumortier, J, Di Martino, V, Radenne, S, De Ledinghen, V, D’Alteroche, L, Silvain, C, Besch, C, Perré, P, Botta-Fridlund, D, Francoz, C, Habersetzer, F, Montialoux, H, Abergel, A, Debette-Gratien, M, Rohel, A, Vallée, J.C.D, Pageaux, G.-P

Get full text

Renal Dysfunction in Liver Transplant Patients Treated with Sofosbuvir Based-Regimen for HCV Recurrence: Results from a Large French Prospective Multicentric ANRS CO23 Cupilt by Anty, R, Coilly, A, Fougerou, C, De Ledinghen, V, Houssel-Debry, P, Duvoux, C, Di Martino, V, Radenne, S, Kamar, N, D’Alteroche, L, Canva, V, Lebray, P, Moreno, C, Dumortier, J, Silvain, C, Besch, C, Botta-Fridlund, D, Leroy, V, Durand, F, Tran, A, Montialoux, H, Habersetzer, F, Favre, G, Rossignol, E, Rohel, A, Renault, A, Dharancy, S, Danjou, H, Duclos-Vallee, J.-C, Pageaux, G.-P

Get full text

Should we keep using Ribavirin to Treat Hepatitis C Recurrence after Liver Transplantation? Results from the CO23 ANRS Cupilt Study by Houssel-Debry, P, Duvoux, C, Coilly, A, Fougerou-Leurent, C, Jezequel, C, De Ledinghen, V, Radenne, S, Kamar, N, Leroy, V, Di Martino, V, D’Alteroche, L, Canva, V, Conti, F, Dumortier, J, Montialoux, H, Lebray, P, Botta-Fridlund, D, Anty, R, Moreno, C, Silvain, C, Besch, C, Perre, P, Durand, F, Abergel, A, Habersetzer, F, Debette-Gratien, M, Rohel, A, Diallo, A, Rossignol, E, Veislinger, A, Danjou, H, Duclos-Vallee, J.-C, Pageaux, G.-P

“…EASL International Liver Congress, APR 13-17, 2016, Barcelona, SPAIN…”
Get full text

P0137 : Safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation. Analysis from a French multicenter, open-label study (ANRS HC29 bocepretransplant) by Fontaine, H, Maynard-Muet, M, Bouix, C, Botta-Fridlund, D, D’Alteroche, L, Conti, F, Pageaux, G.-P, Leroy, V, Métivier, S, Anty, R, Durand, F, Canva, V, Lebray, P, Alric, L, Duvoux, C, Petrov-Sanchez, V, Beaulieux, F, Willems, C, Paul, C, Pradat, P, Duclos-Vallée, J.-C, Samuel, D

Get full text

LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program by Hezode, C, De Ledinghen, V, Fontaine, H, Zoulim, F, Lebray, P, Boyer, N, Larrey, D, Silvain, C, Botta-Fridlund, D, Leroy, V, Bourliere, M, D’Alteroche, L, Hubert-Fouchard, I, Guyader, D, Rosa, I, Nguyen-Khac, E, Di Martino, V, Carrat, F, Fedchuk, L, Akremi, R, Bennai, Y, Bronowicki, J.-P

Get full text

O109 : Treatment of severe HCV-recurrence after liver transplantation using sofosbuvir-based regimens: The ANRS CO23 CUPILT study by Dumortier, J, Botta-Fridlund, D, Coilly, A, Leroy, V, Fougerou-Leurent, C, Danjou, H, Radenne, S, Durand, F, Kamar, N, di Martino, V, de Ledinghen, V, Houssel-Debry, P, d’Alteroche, L, Duvoux, C, Conti, F, Canva, V, Diallo, A, Rohel, A, Duclos-Vallée, J.-C, Pageaux, G.-P

Get full text

P0804 : Efficacy of sofosbuvir-based treatment regimens in HIV/HCV co-infected patients after liver transplantation: The ANRS CO23 CUPILT study by Antonini, T.M, Coilly, A, Radenne, S, Veislinger, A, Botta-Fridlund, D, Durand, F, Houssel-Debry, P, Kamar, N, Canva, V, Perre, P, Bertucci, I, Dumortier, J, Leroy, V, Samuel, D, Pageaux, G.-P, Duclos-Vallee, J.-C

Get full text

European collaborative study on factors influencing outcome after liver transplantation for hepatitis C by Féray, Cyrille, Caccamo, Lucio, Alexander, Graeme J.M., Ducot, Béatrice, Gugenheim, Jean, Casanovas, Teresa, Loinaz, Carmelo, Gigou, Michele, Burra, Patrizia, Barkholt, Lisbeth, Esteban, Raffael, Bizollon, Thierry, Lerut, Jan, Minello–Franza, Anne, Bernard, Pierre–Henri, Nachbaur, Karl, Botta–Fridlund, Danielle, Bismuth, Henri, Schalm, Solko W., Samuel, Didier

“…Background & Aims: Liver transplantation for hepatitis C virus (HCV)-related liver disease is characterized by frequent graft infection by HCV. The prognosis…”
Get full text

G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort by Coilly, A, Fougerou, C, De Ledinghen, V, Houssel-Debry, P, Duvoux, C, Di Martino, V, Radenne, S, Kamar, N, D’Alteroche, L, Leroy, V, Canva, V, Lebray, P, Moreno, C, Dumortier, J, Silvain, C, Besch, C, Perre, P, Botta-Fridlund, D, Anty, R, Rohel, A, Renault, A, Danjou, H, Duclos-Vallee, J.-C, Pageaux, G.-P

Get full text

1422 END OF TREATMENT RESPONSE AFTER PROTEASE INHIBITOR (PI)- BASED THERAPY FOR HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A MULTICENTRIC EUROPEAN EXPERIENCE by Coilly, A, Dumortier, J, Botta-Fridlund, D, Latournerie, M, Leroy, V, Pageaux, G.-P, Giostra, E, Moreno, C, Roche, B, Lebray, P, Radenne, S, Saouli, A.-C, Calmus, Y, Alric, L, Debette-Gratien, M, De Ledinghen, V, Durand, F, Duvoux, C, Samuel, D, Duclos-Vallée, J.-C

Get full text

520 INFRATHERAPEUTIC DOSES OF CALCINEURIN INHIBITORS ARE POSSIBLE WITHOUT CHRONIC REJECTION AFTER LIVER TRANSPLANTATION by Barbier, L.A, Garcia, S, Borentain, P, Botta-Fridlund, D, Le Treut, Y.-P, Hardwigsen, J

Get full text

Comparative study of CYP1A1 induction by 3-methylcholanthrene in various human hepatic and epidermal cell types by Delescluse, C., Ledirac, N., de Sousa, G., Pralavorio, M., Botta-Fridlund, D., Letreut, Y., Rahmani, R.

“…Hepatocytes and keratinocytes are among the most widely used cells in pharmaco-toxicology, but a limitation of these models is the provision of human tissues…”
Get full text

Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study by Portal, I., Bourlière, M., Halfon, P., De Lédinghen, V., Couzigou, P., Bernard, P. H., Blanc, F., Caroli-Bosc, F., Arpurt, J. P., Vetter, D., Mathieu-Chandelier, C., Chazouillères, O., Thiefin, G., Pol, S., Sogni, P., Abergel, A., Bailly, F., Picon, M., Debonne, J. M., Zamora, C., Alleman, I., Moreau, X., Doll, F., Eugène, C., Ducloux, S., Larrey, D., Ouzan, D., Grimaud, J. C., Gouvernet, J., Botti, G., Gérolami, V., Khiri, H., Gérolami, A., Gauthier, A. P., Botta-Fridlund, D.

“…Low pretreatment viral load has consistently been shown to be an independent predictor of sustained response (SR) in patients with chronic hepatitis C…”
Get full text

115 PRE TRANSPLANT AFP LEVEL IS A SIMPLE AND USEFUL TEST FOR A CONTROLLED EXPANSION OF MILAN CRITERIA IN LIVER TRANSPLANT CANDIDATES FOR HEPATOCELLULAR CARCINOMA by Duvoux, C, Decaens, T, Pessione, F, Badran, H, Compagnon, P, Piardi, T, Muscari, F, Francoz, C, Salame, E, Dharancy, S, Radenne, S, Neau-Cransac, M, Stacchini-Myx, A, Dumortier, J, Pageaux, G.P, Duclos-Vallée, J, Hilleret, M.-N, Lebray, P, Chazouillères, O, Botta-Fridlund, D, Conti, F, Abergel, A, Gratien, M, Cherqui, D, Thoraval, F. Roudot

Get full text